**2020 surveillance –** [**Cirrhosis in over 16s: assessment and management (2016)**](https://www.nice.org.uk/guidance/ng50) **NICE guideline NG50**

**Stakeholder consultation comments form - proposal for a partial update**

Consultation on the proposal for a partial updateopens: **27July 2020**

Comments on proposal to be submitted: **no later than 5pm, 7 August 2020**

|  |
| --- |
| **Please enter the name of your registered stakeholder or respondent organisation below.**Please use this form for submitting your comments to NICE. 1. Please put each new comment in a new row.
2. Please note – we cannot accept comments forms with attachments such as research articles, letters or leaflets. If we receive forms with attachments we will return them without reading the comments. If you resubmit the comments on a form without attachments, this must be by the consultation deadline.
3. If you wish to draw our attention to published studies, please supply the full reference.
4. If you’re commenting for an organisation, your organisation needs to be [registered as a stakeholder](https://www.nice.org.uk/get-involved/stakeholder-registration).

Not eligible? Contact the [registered stakeholder organisation](https://www.nice.org.uk/guidance/ng50/documents/stakeholder-list-4)  that most closely represents your interests and pass your comments to them.We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation. |
| Organisation name – Stakeholder or respondent (if you are commenting as an individual rather than a registered stakeholder or respondent organisation, please leave blank): |  |
| DisclosurePlease disclose whether the organisation has any past or current, direct or indirect links to, or receives funding from, the tobacco industry. |  |
| Name of commentator: |  |

[Developing NICE guidelines: the manual](https://www.nice.org.uk/process/pmg20/chapter/1-introduction-and-overview) gives an overview of the processes used in surveillance reviews of NICE clinical guidelines.

| **ID** | **Questions**  | **Overall response**yes / no | **Comments**Please insert each new comment in a new row |
| --- | --- | --- | --- |
| 1 | Do you agree with the proposal for a partial update of the guideline? |  |  |
| 2 | Do you have any comments on areas excluded from the scope of the guideline? |  |  |
| 3 | Do you have any comments on equalities issues? |  |  |
| 4 | Monitoring (oesophageal varices): How often (and why) are non-invasive (platelet count, spleen length, and platelet count‐to‐spleen length ratio) tests used in the detection varices in people with cirrhosis in the UK as an alternative to endoscopy? |  |  |
| 5 | Monitoring (oesophageal varices): Is evidence available on the long-term outcomes (mortality and bleeding events) of non-invasive (platelet count, spleen length, and platelet count‐to‐spleen length ratio) tests versus endoscopy in the detection of varices in people with cirrhosis? |  |  |
| 6 | NICE acknowledges that services and treatment may be affected by the current COVID-19 situation, however most of the content of the guideline was developed before this arose. Please tell us if there are any particular issues we should be considering? |  |  |

**Please email this form to:** **surveillance@nice.org.uk**

**Closing date: 5pm, 7 August 2020**

**PLEASE NOTE:**

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE’s reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.